Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vidaza
Pharma
BMS, BeiGene end legacy Celgene deal years after China ban
Bristol Myers will return about 23.3 million shares of BeiGene, worth about $340 million, to end the companies' partnership in China.
Angus Liu
Aug 3, 2023 10:25am
Sevier's Tibsovo gets FDA nod in combo with BMS' Vidaza in AML
May 26, 2022 10:02am
Astellas finds the silver lining in failed trial for Xospata
Dec 14, 2021 2:57am
A trial win could bless Servier's Tibsovo with a 3rd cancer nod
Dec 11, 2021 7:01am
Bristol Myers' aging Vidaza goes oral with FDA nod in AML
Sep 2, 2020 9:40am
BeiGene hits back at allegations of faked sales numbers
Sep 9, 2019 10:57am
